Compare Abbott Laboratories (ABT) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs FTAI Aviation Ltd — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while FTAI Aviation Ltd trades at $213.16 (market cap $23.33B). The key difference: Abbott Laboratories is far larger — about 7.2× FTAI Aviation Ltd's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | FTAI | |
|---|---|---|
Market Cap | $166.94B | $23.33B |
Sector | Health | Industrials |
52-Week High | $136.62 | $310.04 |
52-Week Low | $82.57 | $109.76 |
Enterprise Value | $193.69B | $26.37B |
Dividend Yield | 2.63% | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
FTAI Aviation trades at $241.54, down 2.63% amid a bearish technical signal, though it remains supported by strong profitability with a 34.99% gross margin and 226.91% ROE. Recent earnings have missed expectations, but revenue growth is projected to rise from $2.51B in 2025 to $2.8B in 2026. Positive news includes a strategic collaboration for Boeing 737-800 freighters and a $0.45 dividend announcement.
The outlook is mixed: robust analyst consensus (100% buy ratings) and innovation in data center power solutions offer upside, but high valuations (P/E 48.11) and consecutive earnings misses pose risks. Investors should weigh growth potential against execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
